Post by
stargazer1 on Dec 27, 2023 3:22pm
# neuron injury cases USA + global & its effect on stock's $
Spinal Cord Injury: USA: 300,000 people with spinal cord injury. 18,000 new cases yearly.
Globally 23 MILLION cases, with 375,000 new cases a year.
Stroke: USA 7 million people, with 800,000 new cases a year
Globally 100 million, with 12 million new cases a year
There is no medical treatment available for these people
Plus multiple other neuron injury cases such as Alzheimer's etc.
FDA has given the company fast track approval. If the trials show results, the FDA will quickly approve the drug. Fast track approval is rarely given. A company has to show that their medication will probably work. For us, it took a long time, but after reviewing the company's work to date, it was given. That means that the FDA is convinced that the company's drug will help people with spinal cord injuries, including severe injuries, plus that it will help in other neuron injuries, such as stroke.
As you saw, this includes millions of millions of people. The drug works especially well with new injuries. And there are even millions of those every year.
In the USA alone, medicare will pay for even highly priced drugs for these cases, as long as the drug is very effective. That means that the person recovers from the neuron injury and thus will not burden medicare with a chronic financial burden.
All this means that our stock price could reach over $100/share, depending on how effective it works.
And our stock, even with its parabolic move, is only $2 ??? It should be no trouble reaching $5, and even higher.
$2 is a steal, and the cops won't even be able to arrest us for stealing. They'll just be mad that, unlike us, they didn't know about it.